Axsome Therapeutics (NASDAQ:AXSM - Free Report) had its price objective boosted by Robert W. Baird from $160.00 to $162.00 in a report released on Tuesday morning, Marketbeat reports. They currently have an outperform rating on the stock.
Several other brokerages have also issued reports on AXSM. William Blair reaffirmed an "outperform" rating on shares of Axsome Therapeutics in a research report on Tuesday, February 18th. Wells Fargo & Company increased their price objective on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. HC Wainwright restated a "buy" rating and set a $200.00 price target on shares of Axsome Therapeutics in a research note on Thursday, April 3rd. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They set a "buy" rating and a $176.00 price objective for the company. Finally, Morgan Stanley upped their target price on Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $172.14.
Get Our Latest Report on Axsome Therapeutics
Axsome Therapeutics Trading Down 1.0 %
NASDAQ:AXSM traded down $1.10 during mid-day trading on Tuesday, hitting $107.76. 435,267 shares of the stock traded hands, compared to its average volume of 682,708. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The stock has a market capitalization of $5.31 billion, a price-to-earnings ratio of -17.99 and a beta of 0.46. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13. The firm's 50 day moving average is $112.01 and its two-hundred day moving average is $104.59.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. On average, equities research analysts predict that Axsome Therapeutics will post -2.79 earnings per share for the current year.
Insider Activity
In related news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 22.30% of the company's stock.
Hedge Funds Weigh In On Axsome Therapeutics
A number of hedge funds have recently made changes to their positions in AXSM. Barclays PLC raised its stake in Axsome Therapeutics by 279.6% in the 3rd quarter. Barclays PLC now owns 61,785 shares of the company's stock valued at $5,552,000 after purchasing an additional 45,509 shares during the last quarter. Franklin Resources Inc. grew its stake in Axsome Therapeutics by 47.5% during the 3rd quarter. Franklin Resources Inc. now owns 160,534 shares of the company's stock valued at $13,713,000 after acquiring an additional 51,696 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Axsome Therapeutics by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock valued at $19,062,000 after acquiring an additional 27,534 shares during the last quarter. Pallas Capital Advisors LLC purchased a new position in Axsome Therapeutics in the 4th quarter worth approximately $2,237,000. Finally, Flower City Capital acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth approximately $254,000. Institutional investors and hedge funds own 81.49% of the company's stock.
Axsome Therapeutics Company Profile
(
Get Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
